These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 17486110)

  • 1. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.
    Galvão DA; Taaffe DR; Spry N; Newton RU
    Prostate Cancer Prostatic Dis; 2007; 10(4):340-6. PubMed ID: 17486110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    J Clin Oncol; 2010 Jan; 28(2):340-7. PubMed ID: 19949016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.
    Segal RJ; Reid RD; Courneya KS; Malone SC; Parliament MB; Scott CG; Venner PM; Quinney HA; Jones LW; D'Angelo ME; Wells GA
    J Clin Oncol; 2003 May; 21(9):1653-9. PubMed ID: 12721238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review.
    Bylow K; Mohile SG; Stadler WM; Dale W
    Cancer; 2007 Dec; 110(12):2604-13. PubMed ID: 17960609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis risk and interest in strength training in men receiving androgen ablation therapy for locally advanced prostate cancer.
    Ott C; Fulton MK
    J Am Acad Nurse Pract; 2005 Mar; 17(3):113-22. PubMed ID: 15748224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    Prostate Cancer Prostatic Dis; 2009; 12(3):233-40. PubMed ID: 19488067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    J Urol; 2011 Oct; 186(4):1291-7. PubMed ID: 21849187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient.
    Tombal B
    Urol Int; 2009; 83(4):373-8. PubMed ID: 19996641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    Eastham JA
    J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications of androgen deprivation therapy in prostate cancer.
    Schwandt A; Garcia JA
    Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
    Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
    Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS; Ryan CW; Jung LL
    J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.